TKG Advisors LLC Purchases 598 Shares of Merck & Co., Inc. (NYSE:MRK)

by · The Cerbat Gem

TKG Advisors LLC grew its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,247 shares of the company’s stock after acquiring an additional 598 shares during the period. TKG Advisors LLC’s holdings in Merck & Co., Inc. were worth $1,959,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Capital International Investors lifted its position in shares of Merck & Co., Inc. by 3,714.9% in the first quarter. Capital International Investors now owns 6,023,853 shares of the company’s stock valued at $794,847,000 after buying an additional 5,865,948 shares during the last quarter. Capital World Investors raised its stake in Merck & Co., Inc. by 67.6% in the 1st quarter. Capital World Investors now owns 13,954,017 shares of the company’s stock valued at $1,841,233,000 after acquiring an additional 5,627,923 shares during the period. Swedbank AB bought a new stake in Merck & Co., Inc. in the 1st quarter valued at $724,776,000. International Assets Investment Management LLC boosted its position in Merck & Co., Inc. by 11,876.3% during the third quarter. International Assets Investment Management LLC now owns 2,971,554 shares of the company’s stock worth $337,450,000 after purchasing an additional 2,946,742 shares during the period. Finally, Wulff Hansen & CO. raised its position in shares of Merck & Co., Inc. by 11,860.9% in the second quarter. Wulff Hansen & CO. now owns 2,494,199 shares of the company’s stock valued at $308,782,000 after purchasing an additional 2,473,346 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, October 3rd. Bank of America lowered their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Wells Fargo & Company dropped their target price on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating for the company in a report on Friday. Wolfe Research upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Citigroup lowered their price target on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.93.

View Our Latest Stock Analysis on MRK

Merck & Co., Inc. Price Performance

Shares of MRK traded down $0.03 during mid-day trading on Monday, reaching $101.85. The company had a trading volume of 1,224,446 shares, compared to its average volume of 8,822,222. The company has a market capitalization of $257.97 billion, a price-to-earnings ratio of 21.36, a P/E/G ratio of 1.46 and a beta of 0.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. The company’s 50 day simple moving average is $112.29 and its 200 day simple moving average is $120.81. Merck & Co., Inc. has a 1-year low of $98.60 and a 1-year high of $134.63.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analysts’ expectations of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 37.32%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Analysts expect that Merck & Co., Inc. will post 7.76 EPS for the current year.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles